The Authors’ aim is to report on their experience in treating superficial bladder cancer with Bacillus Calmette-Guerin, comparing the results with other kinds of therapy.
ProutG.R. Jr.: Personal communication from data obtained by the statistical Center of the National Bladder Cancer Group, 1986.
2.
MoralesA., EidingerD., BruceA.W.: Intracavitary Bacillus Calmette-Guerin in the treatment of superficial bladder tumours. J. Urol., 116: 180, 1976.
3.
DeKernionJ.B., HuangM.Y., LindnerA., SmithR.B., KauffmanI.J.: Management of superficial bladder tumours and carcinoma in situ with Bacillus Calmette-Guerin. J. Urol., 133: 598, 1985.
4.
BrosmanS.A.: The use of Bacillus Calmette-Guerin in the therapy of bradder carcinoma in situ. J. Urol., 134: 36, 1985.
5.
LammD.L.: Bacillus Calmette-Guerin immunotherapy for bladder cancer. J. Urol., 134: 40, 1985.
6.
LammD.L., StodgillV.D., StodgillB.J., CrispenR.G.: Complications of Bacillus Calmette-Guerin immunotherapy in 1278 patients with bladder cancer. J. Urol., 135: 272, 1986.
7.
MartinezPineiro J.A.: BCG vaccine in superficial bladder tumours: eight years later. Eur. Urol., 132, 457, 1984.
8.
DebruyneF.M., Van derMeijden A.P., GeboersA.D., FranssenM.P., Van LeeuwenM.J., SteerenbergP.A., De JongW.H., RuitenbergJ.J.: BCG (RIVM) versus mitomycin intravesical therapy in superficial bladder cancer. First results of a randomized, prospective trial. Urol., 31 (suppl. 3): 20, 1988.
9.
PaganoF., BassiP., MilaniC., MeneghiniC., MarazziD., GarbeglioA.: A low dose Bacillus Calmette-Guerin regimen in superficial bladder cancer therapy: is it effective? J. Urol., 146: 32–5, 1991.
10.
HudsonM.A., RatliffT.L., GillenD.P., HaafE.O., DresnerS.M., CatalonaW.J.: Single course versus maintenance Bacillus Calmette-Guerin therapy for superficial bladder tumors: a prospective, randomized trial. J. Urol., 138: 295, 1987.
11.
StegA., LeleuC., Boccon-GibodL., DebrèB.: Traitment des tumours superficielles de la véssie par BCG-therapie intravesicale. In: International Workshop in Urology. New Trends in bladder cancer chemotherapy. Di SilverioF., StegA. Eds. Roma. Acta Medica Edizioni e congressi, 203–12, 1988.
12.
SolowayM.S., PerryA.: Bacillus Calmette-Guerin for treatment of superficial transitional cell carcinoma of the bladder in patiens who have failed Thiotepa and/or Mitomycin C. J. Urol., 137: 871, 1985.
13.
CatalonaW.J., HudsonM.A., GillenD.P., AndrioleL.G., RatliffT.L.: Risks and benefits of repeated courses of intravesical Bacillus Calmette-Guerin therapy for superficial bladder cancer. J. Urol., 137: 220, 1987.
14.
WitjesJ.A., DebruyneF.M.J.: Use of intravesical Bacillus Calmette-Guerin in the treatment of superficial transitional cell carcinoma of the bladder: an overview. Urol. Int., 45: 129–36, 1990.
